



Final Appraisal Recommendation

Advice No: 0314 – January 2014

Linacotide (Constella[®]▼) 290 microgram hard capsules

Submission by Allergan Ltd

Recommendation of AWMSG

Linacotide (Constella[®]▼) is recommended as an option for restricted use within NHS Wales.

Linacotide (Constella[®]▼) should be restricted for use in the following subpopulation within its licensed indication for the symptomatic treatment of moderate to severe irritable bowel syndrome (IBS) with constipation in adults:

- Patients who have not responded adequately to or cannot tolerate antispasmodics and/or laxatives.

Linacotide (Constella[®]▼) is not recommended for use within NHS Wales outside of this subpopulation.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 948), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Almirall Ltd
Date of first issue	January 2014
Last reviewed	March 2017

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 0314:
linacotide (Constella[®]▼) 290 microgram hard capsules. January 2014.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.